阿托伐他汀联合单硝酸异山梨酯治疗冠心病心绞痛的临床效果及对CHO、hs-CRP的影响

Effect of atorvastatin combined with isosorbide mononitrate on coronary heart disease and angina pectoris and its effects on CHO and hs-CRP

目的对冠心病心绞痛患者采用阿托伐他汀联合硝酸异山梨酯治疗效果以及对CHO、hs-CRP的影响进行分析和讨论.方法选取本院2017年2月至2017年12月的冠心病心绞痛患者72例为研究对象,按照不同治疗方法将其平均分为两组,各36例.对照组患者接受单一的单硝酸异山梨酯治疗,研究组患者接受阿托伐他汀联合单硝酸异山梨酯治疗,对两组治疗效果以及CHO和hs-CRP水平进行对比.结果研究组总有效率94.44%高于对照组72.22%,差异有统计学意义（P〈0.05）;研究组CHO、hs-CRP水平分别为（3.09±0.71）mmol/L、（4.65±0.92）mg/L,均低于对照组,差异有统计学意义（P〈0.05）;研究组心绞痛发作次数、心绞痛持续时间分别为（2.42±2.19）次/周、（2.06±1.29）min/次,均优于对照组,差异有统计学意义（P〈0.05）.结论在治疗冠心病心绞痛的过程中,应用阿托伐他汀联合单硝酸异山梨酯治疗方案,不仅可以改善患者临床症状以及CHO和hs一CRP水平,同时也可以促进治疗效果提高,在临床中值得不断采纳和推广.

Objective To analyze and discuss the effect of atorvastatin combined with isosorbide dinitrate on CHO and hs-CRP in patients with coronary heart disease and angina pectoris. Methods 72 cases of coronary heart disease with angina pectoris in our hospital from February 2017 to December 2017 were divided into two groups according to different treatment methods, 36 cases in each group. The control group was treated with isosorbide mononitrate, the study group received atorvastatin combined with isosorbide mononitrate treatment regimen. The clinical effect and the levels of CHO and hs-CRP of the two groups were compared. Results The total effective rate of the study group was higher than that of the control group （94.44% vs.72.22%）, with statistically significant difference （P〈0.05）. After treatment, the levels of CHO and hs-CRP of the study group were （3.09±0.71） mmol/L and （4.65±0.92） mg/L, which were lower than those of the control group, with statistically significant differences （P〈0.05）; the number of angina attacks and the duration of angina pectoris of the study group were （2.42±2.19） times/week and （2.06±1.29） min/times, which were better than those of the control group, with statistically signifcant differences （P〈0.05）. Conclusion In the treatment of coronary heart disease with angina pectoris, the application of atorvastatin combined with isosorbide mononitrate can not only improve the clinical symptoms and CHO and hs-CRP levels, promote the improvement of therapeutic effect, worthy of continuous adoption and promotion.